REGULATED INFORMATION
GHENT, Belgium, 29 July 2015 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Taube Hodson Stonex Partners LLP.
Taube Hodson Stonex Partners LLP notified Ablynx that they have dropped below the 5% threshold and now hold 2,410,681 Ablynx shares, which represent 4.42% of the current 54,487,457 outstanding Ablynx shares.
Full versions of all transparency notifications are available on Ablynx website, under the section Investors:
http://www.ablynx.com/investors/share-information/major-shareholders/.
About Ablynx
Ablynx:
http://www.ablynx.com/ is a biopharmaceutical company engaged in the development of Nanobodies®:
http://www.ablynx.com/technology-innovation/understanding-nanobodies/, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes:
http://www.ablynx.com/rd-portfolio/overview/ in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Merck Serono, Novartis and Taisho Pharmaceutical. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com:
http://www.ablynx.com.
Voor bijkomende informatie, gelieve contact op te nemen met
Ablynx:
Dr Edwin Moses
Gedelegeerd Bestuurder
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20
Volg ons op Twitter @AblynxABLX
Ablynx media relaties Instinctif Partners:
Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx@instinctif.com:
mailto:ablynx@instinctif.com
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx@instinctif.com:
mailto:ablynx@instinctif.com%20
http://hugin.info/137912/R/1941813/702049.pdf
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire